Background: Ensifentrine, a novel PDE 3/4 inhibitor, has demonstrated significantly improved lung function and reduced exacerbation in previously trials, predominantly conducted in western populations. However, efficacy and safety data on its use in COPD patients of Chinese remain limited. Therefore, we aimed to evaluate the efficacy and safety of nebulized ensifentrine compared with placebo in Chinese participants with COPD. Methods: A phase III multicenter, randomized, double-blind, placebo-controlled trial was conducted between March 2023 and March 2025. The study enrolled patients with moderate-to-severe symptomatic COPD, randomized to ensifentrine group or placebo group in ratio of 5:3, stratified by maintenance therapy and smoking status. The primary endpoint was the improvement in lung function measured by FEV1 AUC0-12h. Other endpoints include quality of life, symptoms and exacerbation. Results: A total of 525 participants were included in the analysis, with 45.9% receiving concomitant maintenance therapy. Ensifentrine treatment significantly improved average FEV1 AUC0-12h versus placebo (110 ml [95% CI: 69-151], p<0.0001). The improvement in lung function was consistent across clinically relevant subgroups, including participants with and without maintenance therapy, as well as participants with moderate and severe COPD. Ensifentrine treatment significantly improved TDI and showed improvement on ERS and SGRQ versus placebo. Ensifentrine treatment showed the trend of reducing the rate of moderate-to-severe exacerbations and increased time to first exacerbation. Adverse event rates were similar between ensifentrine and placebo groups. Conclusions: Ensifentrine significantly improved lung function, symptoms, and quality of life in a Chinese COPD population.